cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications

Ancans, 2012, Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development, Front. Immunol., 3, 253, 10.3389/fimmu.2012.00253

Andrews, 2014, Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells, Nat. Biotechnol., 32, 724, 10.1038/nbt.2973

Andrews, 2015, Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI), Regen. Med., 10, 1, 10.2217/rme.14.93

Carpenter, 2015, Concise review: making and using clinically compliant pluripotent stem cell lines, Stem Cells Transl. Med., 4, 381, 10.5966/sctm.2014-0202

Chen, 2011, Chemically defined conditions for human iPSC derivation and culture, Nat. Methods, 8, 424, 10.1038/nmeth.1593

Chen, 2012, Scalable GMP compliant suspension culture system for human ES cells, Stem Cell Res. (Amst.), 8, 388, 10.1016/j.scr.2012.02.001

Chou, 2011, Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures, Cell Res., 21, 518, 10.1038/cr.2011.12

Chou, 2015, A facile method to establish human induced pluripotent stem cells from adult blood cells under feeder-free and xeno-free culture conditions: a clinically compliant approach, Stem Cells Transl. Med., 4, 320, 10.5966/sctm.2014-0214

Crook, 2007, The generation of six clinical-grade human embryonic stem cell lines, Cell Stem Cell, 1, 490, 10.1016/j.stem.2007.10.004

Dowey, 2012, Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression, Nat. Protoc., 7, 2013, 10.1038/nprot.2012.121

Ellerström, 2006, Derivation of a xeno-free human embryonic stem cell line, Stem Cells, 24, 2170, 10.1634/stemcells.2006-0130

Fairchild, 2015, Taming the lion: the challenge of immunity in regenerative medicine, Regen. Med., 10, 227, 10.2217/rme.15.15

Goh, 2013, A systematic evaluation of integration free reprogramming methods for deriving clinically relevant patient specific induced pluripotent stem (iPS) cells, PLoS ONE, 8, e81622, 10.1371/journal.pone.0081622

Ichida, 2009, A small-molecule inhibitor of tgf-β signaling replaces sox2 in reprogramming by inducing nanog, Cell Stem Cell, 5, 491, 10.1016/j.stem.2009.09.012

Lee, 2012, Activation of innate immunity is required for efficient nuclear reprogramming, Cell, 151, 547, 10.1016/j.cell.2012.09.034

Lowenthal, 2012, Specimen collection for induced pluripotent stem cell research: harmonizing the approach to informed consent, Stem Cells Transl. Med., 1, 409, 10.5966/sctm.2012-0029

Mack, 2011, Generation of induced pluripotent stem cells from CD34+ cells across blood drawn from multiple donors with non-integrating episomal vectors, PLoS ONE, 6, e27956, 10.1371/journal.pone.0027956

Malik, 2013, A review of the methods for human iPSC derivation, Methods Mol. Biol., 997, 23, 10.1007/978-1-62703-348-0_3

Momčilović, 2014, Genome wide profiling of dopaminergic neurons derived from human embryonic and induced pluripotent stem cells, Stem Cells Dev., 23, 406, 10.1089/scd.2013.0412

Nie, 2014, Scalable passaging of adherent human pluripotent stem cells, PLoS ONE, 9, e88012, 10.1371/journal.pone.0088012

Okita, 2011, A more efficient method to generate integration-free human iPS cells, Nat. Methods, 8, 409, 10.1038/nmeth.1591

Pei, 2015, A platform for rapid generation of single and multiplexed reporters in human iPSC lines, Sci. Rep., 5, 9205, 10.1038/srep09205

Rao, 2008, Scalable human ES culture for therapeutic use: propagation, differentiation, genetic modification and regulatory issues, Gene Ther., 15, 82, 10.1038/sj.gt.3303061

Rao, 2008, Alternative sources of pluripotent stem cells: scientific solutions to an ethical dilemma, Stem Cells Dev., 17, 1, 10.1089/scd.2008.0013

Rao, 2012, Concise review: Cord blood banking, transplantation and induced pluripotent stem cell: success and opportunities, Stem Cells, 30, 55, 10.1002/stem.770

Schlaeger, 2015, A comparison of non-integrating reprogramming methods, Nat. Biotechnol., 33, 58, 10.1038/nbt.3070

Schwartz, 2012, Embryonic stem cell trials for macular degeneration: a preliminary report, Lancet, 379, 713, 10.1016/S0140-6736(12)60028-2

Shaltouki, 2015, Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines, Stem Cell Reports, 4, 847, 10.1016/j.stemcr.2015.02.019

Solomon, 2015, Banking on iPSC--is it doable and is it worthwhile, Stem Cell Rev., 11, 1, 10.1007/s12015-014-9574-4

Stacey, 2013, Banking human induced pluripotent stem cells: lessons learned from embryonic stem cells?, Cell Stem Cell, 13, 385, 10.1016/j.stem.2013.09.007

Swistowski, 2010, Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions, Stem Cells, 28, 1893, 10.1002/stem.499

Tannenbaum, 2012, Derivation of xeno-free and GMP-grade human embryonic stem cells--platforms for future clinical applications, PLoS ONE, 7, e35325, 10.1371/journal.pone.0035325

Turner, 2013, Toward the development of a global induced pluripotent stem cell library, Cell Stem Cell, 13, 382, 10.1016/j.stem.2013.08.003